<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Significance of preoperative C-reactive protein as a parameter in patients with small cell carcinoma of the esophagus</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Dove Medical Press Ltd.</publisher>
				<availability status="unknown"><p>Copyright Dove Medical Press Ltd.</p>
				</availability>
				<date type="published" when="2013-08-21">21 August 2013</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ji</forename><surname>Feng</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Zhao</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin</forename><surname>Liu</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Chen</surname></persName>
						</author>
						<title level="a" type="main">Significance of preoperative C-reactive protein as a parameter in patients with small cell carcinoma of the esophagus</title>
					</analytic>
					<monogr>
						<title level="j" type="main">OncoTargets and Therapy</title>
						<title level="j" type="abbrev">OTT</title>
						<idno type="eISSN">1178-6930</idno>
						<imprint>
							<publisher>Dove Medical Press Ltd.</publisher>
							<biblScope unit="page">1147</biblScope>
							<date type="published" when="2013-08-21">21 August 2013</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.2147/ott.s50039</idno>
					<idno type="PMID">24009425</idno>
					<idno type="PMCID">PMC3758215</idno>
					<ptr type="open-access" target="https://www.dovepress.com/getfile.php?fileID=17240" />
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T01:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>C-reactive protein</term>
					<term>esophageal cancer</term>
					<term>small cell carcinoma</term>
					<term>survival</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: C-reactive protein (CRP) is inversely related to prognosis in many cancers, however, no studies regarding the predictive value of CRP in small cell carcinoma of the esophagus (SCCE) are available. The aim of this study was to determine the prognostic value of preoperative CRP in patients with SCCE. Methods: From January 2001 to December 2010, a retrospective analysis of 43 consecutive patients with SCCE was conducted. Univariate and multivariate analyses were performed to evaluate the prognostic parameters. Results: In our study, elevated CRP levels (.10 mg/L) were found in 16 patients (37.2%). CRP levels were significantly higher in patients with deeply invasive tumors (P = 0.018) and those associated with nodal metastasis (P = 0.018). Patients with CRP #10 mg/L had a significantly better overall survival than patients with CRP .10 mg/L (25.9% vs 6.3%, P = 0.004). Multivariate analyses showed that CRP was a significant predictor for overall survival. CRP .10 mg/L had a hazard ratio of 2.756 (95% confidence interval: 1.115-6.813, P = 0.028) for overall survival. Conclusion: Preoperative CRP is an independent predictive factor for long-term survival in patients with SCCE.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Small cell carcinoma of the esophagus (SCCE) is a rare disease, which was first described in 1952 by McKeown. <ref type="bibr" target="#b0">1</ref> The incidence of SCCE within all esophageal cancers (ECs) is 0.05%-2.4% in Western populations, and this rate rises up to 7.6% in Chinese and Japanese literature. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref> Previous studies suggested that SCCE is a highly aggressive disease with poor prognosis. <ref type="bibr" target="#b2">3</ref> Although advances have occurred in multidisciplinary treatment, the 5-year survival in SCCE is still poor. Therefore, assessing the prognostic factors in SCCE patients will become more and more important.</p><p>Recently, there has been increasing evidence that a systemic inflammatory response is of prognostic value in various cancers. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref> C-reactive protein (CRP) is an index of systemic inflammation. Recent publications have suggested that preoperative CRP is inversely related to prognosis in many cancers; a high level is associated with poor prognosis. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> Furthermore, a few recent studies investigated the value of CRP levels in patients with EC and obtained encouraging results in terms of prognosis prediction. <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref> However, to the best of our knowledge, no studies regarding the predictive value of CRP in SCCE are available. Therefore, the aim of this study was to determine the prognostic value of CRP in patients with SCCE.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods Patients</head><p>From January 2001 to December 2010, a retrospective analysis was conducted of 43 patients with SCCE who underwent curative esophagectomy at Zhejiang Cancer Hospital (Hangzhou, People's Republic of China). All of the patients included in the analysis fit the following criteria: (1) SCCE confirmed by histopathology; (2) limited disease without distal metastasis; (3) curative esophagectomy with margins free of disease. Based on the medical records, the following data were collected for each patient: age, gender, tumor length, tumor location, preoperative CRP, depth of invasion, nodal metastasis, treatment, and other miscellaneous characteristics.</p><p>All of the above patients were followed up by posting letters or by telephone interviews. The last follow-up was November 30, 2011. All subjects gave written informed consent to the study protocol, which was approved by the Ethical Committees of Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preoperative CRP measurement</head><p>Data on preoperative CRP were extracted in a retrospective fashion from the medical records. All blood test results were taken within 1 week prior to surgery. Serum CRP was determined by latex-enhanced homogeneous immunoassay (wide-range) (Hitachi 917; Skill, Munich, Germany). Normal values provided by the manufacturer were lower than 10 mg/L.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjuvant chemoradiotherapy</head><p>Adjuvant chemoradiotherapy was used in 26 cases. Among them, 13 cases were treated with four to six courses of platinum-based combination chemotherapy, eight cases with radiotherapy, and five cases with chemoradiotherapy, respectively. For chemotherapy, eight patients were treated with etoposide plus cisplatin, three with paclitaxel plus cisplatin, and one with 5-fluorouracil plus platinum. For radiotherapy, radiation was delivered from 2 Gy per day, 5 days per week, to a total dose of 45-68 Gy. No patients were treated with neoadjuvant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>statistical analysis</head><p>Statistical evaluation was conducted with SPSS (v17.0; SPSS Inc, Chicago, IL, USA). The patients were divided into two groups according to the CRP measured preoperatively: those with CRP values in the normal range (#10 mg/L) and those with elevated CRP levels (.10 mg/L). The Pearson Chi-squared test was used to determine the significance of differences between the two groups. The overall cumulative probability of survival was calculated by the Kaplan-Meier method, and the difference was assessed by the log-rank test. A univariate analysis was used to examine the association between various prognostic predictors and survival. Possible prognostic factors associated with overall survival were considered in a multivariable Cox proportional hazards regression analysis (Enter). Hazard ratios (HR) with 95% confidence intervals (CI) were used to quantify the strength of the association between predictors and survival. A P-value less than 0.05 was considered to be statistically significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>The baseline characteristics are shown in <ref type="table" target="#tab_0">Table 1</ref>. Among the 43 patients, 13 (30.2%) were women and 30 (69.8%) were men. The mean age was 58.7 Â± 7.8 years, with an age range of 45-74 years.</p><p>There were no significant differences between the two groups in terms of age, gender, tumor location, tumor length, or vessel involvement. However, CRP levels were significantly higher in patients with deeply invasive tumors (T3-4a vs T1-2, P = 0.018) and those associated with nodal metastasis (positive vs negative, P = 0.018) ( <ref type="table" target="#tab_1">Table 2)</ref>.</p><p>Univariate analyses were performed using the Kaplan-Meier method to assess the predictive capability of each variable assessed. Multivariate analyses were then performed with the Cox proportional hazards model. In that survival of SCCE was achieved after esophagectomy with or without adjuvant chemotherapy. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref> There is a strong link between inflammation and cancer. It is well known that cancer promotes the release of proinflammatory cytokines from tumor cells. The cytokines interact with the immunovascular system and facilitate growth, invasion, and metastasis. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref> Recent studies have shown that elevated preoperative serum CRP levels may be associated with tumor size, depth of invasion, and nodal metastasis, resulting in poor prognosis in patients with various cancers, including EC. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b8">9</ref> Thus, in our study, we wanted to determine whether preoperative CRP level is associated with overall survival after esophagectomy for SCCE.</p><p>Our results demonstrated that CRP levels were significantly higher in patients with deeply invasive tumors (P = 0.018) and those associated with nodal metastasis (P = 0.018). This observation is in line with data from Shimada et al <ref type="bibr" target="#b7">8</ref> and Nozoe et al, <ref type="bibr" target="#b8">9</ref> but is contrary to the result of Guillem et al, <ref type="bibr" target="#b9">10</ref> who suggested that preoperative CRP is not significantly correlated with the above clinicopathological factors. However, in our study, no relationship was found between CRP level and tumor size.</p><p>A number of studies have shown that increased preoperative CRP levels in various solid tumors are associated with poor prognosis. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> Shimada et al 8 demonstrated that although the difference in survival was mainly attributable to differences in TNM staging between the low and high CRP groups, preoperative CRP was an independent prognostic factor according to multivariate analysis. In our study, the survival of patients in the high CRP group (.10 mg/L) was significantly worse than that of the low CRP group (#10 mg/L; 25.9% vs 6.3%, P = 0.004). In addition, preoperative CRP was an independent prognostic factor according to multivariate analysis (P = 0.028).</p><p>The reasons why CRP levels can be correlated with prognosis in cancer patients remain to be determined. Any explanation of accumulating data showing that serum CRP is involved in host defenses against infections as highlighted by murine transgenic models must be speculative. <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref> As with other proteic markers of acute inflammation, CRP has several biological functions including complement activation through the classical pathway, opsonization, leukocyte chemotactism, and platelet activation. <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19</ref> The potential limitations of the present study include the relatively small number of patients, as well as the fact that the analysis was retrospective, and the short mean follow-up duration. Furthermore, due to the limited number of patients with SCCE, our analysis may suffer from type I or model, we demonstrated that CRP (HR: 2.756, 95% CI: 1.115-6.813, P = 0.028), and chemoradiotherapy (HR: 0.294, 95% CI: 0.129-0.673, P = 0.004) were independent prognostic factors ( <ref type="table" target="#tab_2">Table 3</ref>). In addition, patients with CRP #10 mg/L had a significantly better overall survival than patients with CRP .10 mg/L (25.9% vs 6.3%, P = 0.004) <ref type="figure" target="#fig_0">(Figure 1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>To the best of our knowledge, this is the first study to determine the prognostic value of preoperative CRP in predicting the prognosis for patients with SCCE. Our study showed that preoperative CRP is an independent predictive factor for long-term survival in patients with SCCE (HR: 2.756, 95% CI: 1.115-6.813, P = 0.028).</p><p>The standard therapy for SCCE has not been yet established. Because of the rarity of SCCE, prospective, randomized controlled trials of its optimal treatment are unlikely. The histology and clinical characteristics of SCCE are similar to small cell carcinoma of the lung (SCCL); subsequently, investigations have recommended that a multimodal approach be used for SCCE as it is for SCCL. <ref type="bibr" target="#b10">11</ref> The most commonly used regimens include platinum-based agents, which are often used for SCCL. <ref type="bibr" target="#b11">12</ref> However, the optimal radiation dose for SCCE has not been established. For patients with limited disease, there were several reports showing that long-term  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OncoTargets and Therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publish your work in this journal</head><p>Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal</p><p>OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.</p><p>OncoTargets and Therapy 2013:6</p><p>type II errors. The results of the study should therefore be regarded with caution. In addition, no control population study was undertaken; hence, there are limitations in the scientific observations. Larger prospective studies will need to be performed to confirm these preliminary results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>Our study showed that preoperative CRP is an independent predictive factor for long-term survival in patients with SCCE. Serum CRP is a simple, reliable, cheap, and reproducible method, for which interpretation is relatively easy in the context of a non-septic neoplasia. We therefore propose pretreatment CRP as a useful adjunct that can be associated in routine practice with pretreatment screening in patients with SCCE.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc>Patients with CRP #10 mg/L had a significantly better 5-year overall survival rate than patients with CRP .10 mg/L (25.9% vs 6.3%, P = 0.004). Abbreviation: CRP, C-reactive protein.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>The baseline characteristics of 43 patients with SCCE</figDesc><table><row><cell>Cases (n, %)</cell></row></table><note>Abbreviations: SCCE, small cell carcinoma of the esophagus; SD, standard deviation.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc>The characteristics between patients with CRP #10 mg/l and .10 mg/l</figDesc><table><row><cell></cell><cell>CRP #10 mg/L</cell><cell>CRP .10 mg/L</cell><cell>P-value</cell></row><row><cell></cell><cell>(n, %)</cell><cell>(n, %)</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell><cell>0.965</cell></row><row><cell>#60</cell><cell>15 (55.6)</cell><cell>9 (56.3)</cell></row><row><cell>.60</cell><cell>12 (44.4)</cell><cell>7 (43.7)</cell></row><row><cell>gender</cell><cell></cell><cell></cell><cell>0.086</cell></row><row><cell>Female</cell><cell>11 (40.7)</cell><cell>2 (12.5)</cell></row><row><cell>Male</cell><cell>16 (59.3)</cell><cell>14 (87.5)</cell></row><row><cell>Tumor length (cm)</cell><cell></cell><cell></cell><cell>0.278</cell></row><row><cell>#3.0</cell><cell>13 (48.1)</cell><cell>5 (31.3)</cell></row><row><cell>.3.0</cell><cell>14 (51.9)</cell><cell>11 (68.7)</cell></row><row><cell>Tumor location</cell><cell></cell><cell></cell><cell>0.141</cell></row><row><cell>Upper/middle</cell><cell>18 (66.7)</cell><cell>7 (43.7)</cell></row><row><cell>lower</cell><cell>9 (33.3)</cell><cell>9 (56.3)</cell></row><row><cell>Vessel involvement</cell><cell></cell><cell></cell><cell>0.719</cell></row><row><cell>negative</cell><cell>20 (74.1)</cell><cell>13 (81.3)</cell></row><row><cell>Positive</cell><cell>7 (25.9)</cell><cell>3 (18.7)</cell></row><row><cell>Depth of invasion</cell><cell></cell><cell></cell><cell>0.018</cell></row><row><cell>T1-2</cell><cell>15 (55.6)</cell><cell>3 (18.7)</cell></row><row><cell>T3-4a</cell><cell>12 (44.4)</cell><cell>13 (81.3)</cell></row><row><cell>nodal metastasis</cell><cell></cell><cell></cell><cell>0.018</cell></row><row><cell>negative</cell><cell>13 (48.1)</cell><cell>2 (12.5)</cell></row><row><cell>Positive</cell><cell>14 (51.9)</cell><cell>14 (87.5)</cell></row></table><note>Abbreviation: CRP, C-reactive protein.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>Univariate and multivariate analyses of overall survival in SCCE patients</figDesc><table><row><cell></cell><cell>Survival (%)</cell><cell>Chi-square</cell><cell>P-value</cell><cell>HR (95% CI)</cell><cell>P-value</cell></row><row><cell>Age (years)</cell><cell></cell><cell>0.686</cell><cell>0.408</cell><cell></cell></row><row><cell>#60</cell><cell>16.7</cell><cell></cell><cell></cell><cell></cell></row><row><cell>.60</cell><cell>21.1</cell><cell></cell><cell></cell><cell></cell></row><row><cell>gender</cell><cell></cell><cell>1.841</cell><cell>0.175</cell><cell></cell></row><row><cell>Female</cell><cell>38.5</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>10.0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Tumor length (cm)</cell><cell></cell><cell>6.846</cell><cell>0.009</cell><cell></cell><cell>0.582</cell></row><row><cell>#3</cell><cell>33.3</cell><cell></cell><cell></cell><cell>1.000</cell></row><row><cell>.3</cell><cell>8.0</cell><cell></cell><cell></cell><cell>1.267 (0.546-2.937)</cell></row><row><cell>Tumor location</cell><cell></cell><cell>0.024</cell><cell>0.877</cell><cell></cell></row><row><cell>Upper/middle</cell><cell>20.0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>lower</cell><cell>16.7</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CRP (mg/L)</cell><cell></cell><cell>8.115</cell><cell>0.004</cell><cell></cell><cell>0.028</cell></row><row><cell>#10</cell><cell>25.9</cell><cell></cell><cell></cell><cell>1.000</cell></row><row><cell>.10</cell><cell>6.3</cell><cell></cell><cell></cell><cell>2.756 (1.115-6.813)</cell></row><row><cell>Vessel involvement</cell><cell></cell><cell>1.068</cell><cell>0.301</cell><cell></cell></row><row><cell>negative</cell><cell>21.2</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>10.0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Depth of invasion</cell><cell></cell><cell>7.433</cell><cell>0.006</cell><cell></cell><cell>0.232</cell></row><row><cell>T1-2</cell><cell>33.3</cell><cell></cell><cell></cell><cell>1.000</cell></row><row><cell>T3-4a</cell><cell>8.0</cell><cell></cell><cell></cell><cell>1.716 (0.708-4.161)</cell></row><row><cell>nodal metastasis</cell><cell></cell><cell>9.687</cell><cell>0.002</cell><cell></cell><cell>0.189</cell></row><row><cell>negative</cell><cell>40.0</cell><cell></cell><cell></cell><cell>1.000</cell></row><row><cell>Positive</cell><cell>7.1</cell><cell></cell><cell></cell><cell>1.891 (0.731-4.892)</cell></row><row><cell>chemoradiotherapy</cell><cell></cell><cell>5.577</cell><cell>0.018</cell><cell></cell><cell>0.004</cell></row><row><cell>no</cell><cell>5.9</cell><cell></cell><cell></cell><cell>1.000</cell></row><row><cell>Yes</cell><cell>26.9</cell><cell></cell><cell></cell><cell>0.294 (0.129-0.673)</cell></row></table><note>Abbreviations: CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; SCCE, small cell carcinoma of the esophagus.</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">submit your manuscript | www.dovepress.com Dovepress Dovepress</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">OncoTargets and Therapy 2013:6 submit your manuscript | www.dovepress.comDovepress Dovepress</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgment</head><p>The authors would like to thank Ms Ying Huang (Department of Nursing, Zhejiang Cancer Hospital) for data collection and statistical analysis.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure</head><p>The authors report no conflicts of interest in this work.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Oat-cell carcinoma of the Åsophagus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Florence</forename><surname>Mckeown</surname></persName>
		</author>
		<idno type="DOI">10.1002/path.1700640420</idno>
		<idno type="PMID">13000600</idno>
		<idno type="ark">ark:/67375/WNG-3ZJZ8G3R-B</idno>
		<idno type="istexId">2850D478C0C6B6C0770FD579B75C8F84C9F77000</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Pathology and Bacteriology</title>
		<title level="j" type="abbrev">J. Pathol.</title>
		<idno type="ISSN">0368-3494</idno>
		<idno type="ISSNe">1555-2039</idno>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="889" to="891" />
			<date type="published" when="1952-10" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Naohiko</forename><surname>Koide</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroyasu</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Akira</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshiyuki</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keiichiro</forename><surname>Koiwai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Naoshi</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shinichi</forename><surname>Miyagawa</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00535-007-2114-0</idno>
		<idno type="PMID">18085349</idno>
		<idno type="ark">ark:/67375/VQC-QC9GJP6N-K</idno>
		<idno type="istexId">868060767DC0A4868195DF450F71D889FE55D72C</idno>
		<ptr type="open-access" target="https://soar-ir.repo.nii.ac.jp/?action=repository_action_common_download&amp;item_id=8103&amp;item_no=1&amp;attribute_id=65&amp;file_no=1" />
	</analytic>
	<monogr>
		<title level="j">Journal of Gastroenterology</title>
		<title level="j" type="abbrev">J Gastroenterol</title>
		<idno type="ISSN">0944-1174</idno>
		<idno type="ISSNe">1435-5922</idno>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="932" to="938" />
			<date type="published" when="2007-12" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Small Cell Carcinomas of the Gastrointestinal Tract: Clinicopathological Features and Treatment Approach</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Baruch</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laura</forename><forename type="middle">H</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jinruh</forename><surname>Shia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">S</forename><surname>Klimstra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">P</forename><surname>Kelsen</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.seminoncol.2006.10.022</idno>
		<idno type="PMID">17270665</idno>
	</analytic>
	<monogr>
		<title level="j">Seminars in Oncology</title>
		<title level="j" type="abbrev">Seminars in Oncology</title>
		<idno type="ISSN">0093-7754</idno>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="43" to="50" />
			<date type="published" when="2007-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Inflammation and cancer: back to Virchow?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fran</forename><surname>Balkwill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alberto</forename><surname>Mantovani</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(00)04046-0</idno>
		<idno type="PMID">11229684</idno>
		<idno type="PII">S0140-6736(00)04046-0</idno>
		<idno type="ark">ark:/67375/6H6-MN9Q6XW0-N</idno>
		<idno type="istexId">6254F8284C2396277DFF03D383AC31868C0C453F</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<title level="j" type="abbrev">The Lancet</title>
		<idno type="ISSN">0140-6736</idno>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="issue">9255</biblScope>
			<biblScope unit="page" from="539" to="545" />
			<date type="published" when="2001-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Cancer-related inflammation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alberto</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Allavena</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Antonio</forename><surname>Sica</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frances</forename><surname>Balkwill</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature07205</idno>
		<idno type="PMID">18650914</idno>
		<idno type="ark">ark:/67375/GT4-CRZS304Q-N</idno>
		<idno type="istexId">92645B3BC261265B58EA4136DC84F0256DCC837E</idno>
		<ptr type="open-access" target="https://air.unimi.it/bitstream/2434/145688/2/Cancer-related%20inflammation_Nature.pdf" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<title level="j" type="abbrev">Nature</title>
		<idno type="ISSN">0028-0836</idno>
		<idno type="ISSNe">1476-4687</idno>
		<imprint>
			<biblScope unit="volume">454</biblScope>
			<biblScope unit="issue">7203</biblScope>
			<biblScope unit="page" from="436" to="444" />
			<date type="published" when="2008-07" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hirofumi</forename><surname>Nakanishi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nobuhito</forename><surname>Araki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ikuo</forename><surname>Kudawara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shigeyuki</forename><surname>Kuratsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Akihiko</forename><surname>Matsumine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masayuki</forename><surname>Mano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Norifumi</forename><surname>Naka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Akira</forename><surname>Myoui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takafumi</forename><surname>Ueda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideki</forename><surname>Yoshikawa</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijc.10343</idno>
		<idno type="PMID">11979429</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Cancer</title>
		<title level="j" type="abbrev">Int. J. Cancer</title>
		<idno type="ISSN">0020-7136</idno>
		<idno type="ISSNe">1097-0215</idno>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="167" to="170" />
			<date type="published" when="2002-04-22" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">C-reactive Protein as a Predictor of Postoperative Infective Complications after Curative Resection in Patients with Colorectal Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonathan</forename><forename type="middle">J</forename><surname>Platt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michelle</forename><forename type="middle">L</forename><surname>Ramanathan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robin</forename><forename type="middle">A</forename><surname>Crosbie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">H</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruth</forename><forename type="middle">F</forename><surname>Mckee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">G</forename><surname>Horgan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donald</forename><forename type="middle">C</forename><surname>Mcmillan</surname></persName>
		</author>
		<idno type="DOI">10.1245/s10434-012-2498-9</idno>
		<idno type="PMID">22805866</idno>
		<idno type="ark">ark:/67375/VQC-HX2JLJV5-W</idno>
		<idno type="istexId">B1970FE25D7FF1635AF922167887FC4F505747BD</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Surgical Oncology</title>
		<title level="j" type="abbrev">Ann Surg Oncol</title>
		<idno type="ISSN">1068-9265</idno>
		<idno type="ISSNe">1534-4681</idno>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="4168" to="4177" />
			<date type="published" when="2012-07-18" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideaki</forename><surname>Shimada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshihiro</forename><surname>Nabeya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shin-Ichi</forename><surname>Okazumi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hisahiro</forename><surname>Matsubara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tooru</forename><surname>Shiratori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Taito</forename><surname>Aoki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Makoto</forename><surname>Sugaya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yukimasa</forename><surname>Miyazawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideki</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shin-Ichi</forename><surname>Miyazaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takenori</forename><surname>Ochiai</surname></persName>
		</author>
		<idno type="DOI">10.1002/jso.10275</idno>
		<idno type="PMID">12884238</idno>
		<idno type="ark">ark:/67375/WNG-6594F8MN-F</idno>
		<idno type="istexId">37800D028B2836F8214BF0AF92BEE81D1B6A6D3F</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Surgical Oncology</title>
		<title level="j" type="abbrev">J. Surg. Oncol.</title>
		<idno type="ISSN">0022-4790</idno>
		<idno type="ISSNe">1096-9098</idno>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="248" to="252" />
			<date type="published" when="2003-07-21" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tadahiro</forename><surname>Nozoe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Saeki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keizo</forename><surname>Sugimachi</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0002-9610(01)00684-5</idno>
		<idno type="PMID">11574097</idno>
		<idno type="PII">S0002-9610(01)00684-5</idno>
		<idno type="ark">ark:/67375/6H6-SF59J0DZ-D</idno>
		<idno type="istexId">36B8910064D2B6CC2F61B5FCAD1BC272A2CF81A7</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Surgery</title>
		<title level="j" type="abbrev">The American Journal of Surgery</title>
		<idno type="ISSN">0002-9610</idno>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="197" to="201" />
			<date type="published" when="2001-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Guillem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Triboulet</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1442-2050.2005.00474.x</idno>
		<idno type="PMID">16045574</idno>
		<idno type="ark">ark:/67375/WNG-N34QNX20-J</idno>
		<idno type="istexId">F41C245CDEBE2D33AFEB316CA2E23F1FFCA8EF75</idno>
	</analytic>
	<monogr>
		<title level="j">Diseases of the Esophagus</title>
		<idno type="ISSN">1120-8694</idno>
		<idno type="ISSNe">1442-2050</idno>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="146" to="150" />
			<date type="published" when="2005-08-01" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Casas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Ferrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Farrus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Casals</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Biete</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1366" to="1372" />
			<date type="published" when="1997" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Small cell oesophageal carcinoma: an institutional experience and review of the literature</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Hudson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Mukherjee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">D L</forename><surname>Crosby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">E</forename><surname>Brewster</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">S</forename><surname>Maughan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Lester</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bjc.6603611</idno>
		<idno type="PMID">17299393</idno>
		<idno type="PMCID">PMC2360086</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/6603611.pdf" />
	</analytic>
	<monogr>
		<title level="j">British Journal of Cancer</title>
		<title level="j" type="abbrev">Br J Cancer</title>
		<idno type="ISSN">0007-0920</idno>
		<idno type="ISSNe">1532-1827</idno>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="708" to="711" />
			<date type="published" when="2007-02-13" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Should We Recommend Surgery to Patients with Limited Small Cell Carcinoma of the Esophagus?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aminah</forename><surname>Jatoi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">C</forename><surname>Miller</surname></persName>
		</author>
		<idno type="DOI">10.1097/jto.0b013e31818dd98f</idno>
		<idno type="PMID">19057258</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Thoracic Oncology</title>
		<title level="j" type="abbrev">Journal of Thoracic Oncology</title>
		<idno type="ISSN">1556-0864</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1373" to="1376" />
			<date type="published" when="2008-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Rozema</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">C</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hendlisz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Van Laethem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Khanfir</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">C</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>El Nakadi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Van Houtte</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1442-2050.2010.01133.x</idno>
		<idno type="PMID">21073624</idno>
		<idno type="ark">ark:/67375/WNG-HJ6K5HZX-Z</idno>
		<idno type="istexId">6F10F41C765D7EE8FD6EDB0C767BB8EEF3A04B3B</idno>
	</analytic>
	<monogr>
		<title level="j">Diseases of the Esophagus</title>
		<idno type="ISSN">1120-8694</idno>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="258" to="264" />
			<date type="published" when="2010-11-12" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Diagnostic Implications of C-Reactive Protein</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">A</forename><surname>Zimmerman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Selzman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Cothren</surname></persName>
		</author>
		<idno type="DOI">10.1001/archsurg.138.2.220</idno>
		<idno type="PMID">12578424</idno>
		<ptr type="open-access" target="https://jamanetwork.com/journals/jamasurgery/articlepdf/394323/srv2003.pdf" />
	</analytic>
	<monogr>
		<title level="j">Archives of Surgery</title>
		<title level="j" type="abbrev">Arch Surg</title>
		<idno type="ISSN">0004-0010</idno>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">220</biblScope>
			<date type="published" when="2003-02-01" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Human C-Reactive Protein Is Protective against Fatal Salmonella enterica Serovar Typhimurium Infection in Transgenic Mice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Szalai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Vancott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Mcghee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Volanakis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Benjamin</surname></persName>
		</author>
		<idno type="DOI">10.1128/iai.68.10.5652-5656.2000</idno>
		<idno type="PMID">10992466</idno>
		<idno type="PMCID">PMC101518</idno>
		<ptr type="open-access" target="https://iai.asm.org/content/68/10/5652.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Infection and Immunity</title>
		<title level="j" type="abbrev">Infection and Immunity</title>
		<idno type="ISSN">0019-9567</idno>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="5652" to="5656" />
			<date type="published" when="2000-10-01" />
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Human C-Reactive Protein Is Protective against Fatal Salmonella enterica Serovar Typhimurium Infection in Transgenic Mice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Szalai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Vancott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Mcghee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Volanakis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Benjamin</surname></persName>
		</author>
		<idno type="DOI">10.1128/iai.68.10.5652-5656.2000</idno>
		<idno type="PMID">10992466</idno>
		<idno type="PMCID">PMC101518</idno>
		<ptr type="open-access" target="https://iai.asm.org/content/68/10/5652.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Infection and Immunity</title>
		<title level="j" type="abbrev">Infection and Immunity</title>
		<idno type="ISSN">0019-9567</idno>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="5652" to="5656" />
			<date type="published" when="2000-10-01" />
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kristine</forename><forename type="middle">H</forename><surname>Allin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">BÃ¸rge</forename><forename type="middle">G</forename><surname>Nordestgaard</surname></persName>
		</author>
		<idno type="DOI">10.3109/10408363.2011.599831</idno>
		<idno type="PMID">22035340</idno>
	</analytic>
	<monogr>
		<title level="j">Critical Reviews in Clinical Laboratory Sciences</title>
		<title level="j" type="abbrev">Critical Reviews in Clinical Laboratory Sciences</title>
		<idno type="ISSN">1040-8363</idno>
		<idno type="ISSNe">1549-781X</idno>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="155" to="170" />
			<date type="published" when="2011-08" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Interleukin 6 and C-reactive protein in esophageal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Magdalena</forename><surname>Groblewska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barbara</forename><surname>Mroczko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dorota</forename><surname>Sosnowska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maciej</forename><surname>Szmitkowski</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cca.2012.05.009</idno>
		<idno type="PMID">22609487</idno>
	</analytic>
	<monogr>
		<title level="j">Clinica Chimica Acta</title>
		<title level="j" type="abbrev">Clinica Chimica Acta</title>
		<idno type="ISSN">0009-8981</idno>
		<imprint>
			<biblScope unit="volume">413</biblScope>
			<biblScope unit="issue">19-20</biblScope>
			<biblScope unit="page" from="1583" to="1590" />
			<date type="published" when="2012-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
